In vivo efficacy of oral and intralesional administration of 2- substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2447-2451

  Fournet, Alain ^a,b   Ferreira, Maria Elena ^b   Rojas De Arias, Antonieta ^b   Torres De Ortiz, Susana ^b   Fuentes, Sandra ^b   Nakayama, Hector ^b   Schinini, Alicia ^b   Hocquemiller, Reynald ^c  

^a Institut de Recherche pour le Developpement Asuncion   (Paraguay)

^b Instituto de Investigaciones en Ciencias de la Salud Universidad Nacional de Asuncion   (Paraguay)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,4 METHYLENEDIOXYPHENYLETHYL)QUINOLINE; 2 PENTYLQUINOLINE; 2 PHENYLQUINOLINE DERIVATIVE; 2 PROPYLQUINOLINE; ANTILEISHMANIAL AGENT; CHIMANINE B; CHIMANINE D; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; LEISHMANIA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

EID: 0029965604     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2447     Document Type: Article

References (20)

1. Afonso, L. C. C., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959.
2. Albrecht, H., H. J. Stellbrink, G. Gross, B. Berg, U. Helmchen, and H. Mensing. 1994. Treatment of atypical leishmaniasis with interferon γ resulting in progression of Kaposi's sarcoma in an AIDS patient. Clin. Invest. 72:1041-1047.
3. Altes, J., A. Salas, M. Riera, M. Udina, A. Galmes, J. Balanzat, A. Ballesteros, J. Buades, F. Salva, and C. Villalonga. 1991. Visceral leishmaniasis: another HIV-associated opportunistic infections? Report of eight cases of the litterature. AIDS 5:201-207.
4. Barral-Netto, M., J. Santana da Silva, A. Barral, and S. Reed. 1995. Upregulation of T-helper 2 and down-regulation of T helper 1 cytokines during murine retrovirus-induced immunodeficiency syndrome enhances susceptibility of a resistant mouse strain to Leishmania amazonensis. Am. J. Pathol. 146:635-642.
5. Berenguer, J., S. Moreno, E. Cercenado, J. C. L. Bernaldo de Quiros, A. Garcia de la Fuente, and E. Bouza. 1989. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann. Intern. Med. 111:129-132.
6. Buffet, P. A., A. Sulahan, Y. J. F. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissue of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
7. Fournet, A., A. Angelo Barrios, V. Muñoz, R. Hocquemiller, A. Cavé, and J. Bruneton. 1993. 2-Substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob. Agents Chemother. 37:859-863.
8. Fournet, A., A. Angelo Barrios, V. Muñoz, R. Hocquemiller, R., F. Roblot, A. Cavé, P. Richomme, and J. Bmneton. 1994. Antiprotozoal activity of quinoline alkaloids isolated from Galipea longiflora, a Bolivian plant used as a treatment for cutaneous leishmaniasis. Phytother. Res. 8:174-178.
9. Fournet, A., J. C. Gantier, A. Gautheret, L. Leysalles, M. H. Munos, J. Mayrargues, H. Moskowitz, R. Hocquemiller, and A. Cavé. 1994. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J. Antimicrob. Chemother. 33:537-544.
10. Fournet, A., R. Hocquemiller, and J. C. Gantier. 1995. Combattre la leishmaniose. Recherche 26:424-429.
11. Fournet, A., R. Hocquemiller, F. Roblot, A. Cavé, P. Richomme, and J. Bruneton. 1993. Les chimanines, nouvelles quinoléines substituées en 2, isolées d'une plante bolivienne antiparasitaire: Galipea longiflora. J. Nat. Prod. 56:1547-1552.
12. Grogl, M., A. M. J. Odula, L. D. C. Cordero, and D. E. Kyle. 1989. Leishmania spp: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:78-90.
13. Grogl, M., T. N. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutancous leishmaniasis. Am. J. Trop. Med. Hyg. 47:117-126.
14. Hill, J. O., R. J. North, and F. M. Collins. 1983. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect. Immun. 39:1087-1094.
15. Ho, J. L., R. Badaro, D. Hatzigeorgiou, S. G. Reed, and W. D. Johnson, Jr. 1994. Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy. Biotherapy 7:223-235.
16. Iwu, M. M., J. E. Jackson, and B. G. Schuster. 1994. Medicinal plants in the fight against leishmaniasis. Parasitol. Today 10:65-68.
17. Munos, M. H., J. Mayrargue, A. Fournet, J. C. Gantier, R. Hocquemiller, and H. Moskowitz. 1994. Synthesis of an antileishmanial alkaloid isolated from Galipea longiflora and of related compounds. Chem. Pharm. Bull. 42:1914-1916.
18. + T cells on experimental infection of susceptible BALB/c mice with Leishmania amazonensis. Acta Trop. 56:111-120.
19. Torre-Cisneros, J., and J. L. Villanueva. 1995. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus. Clin. Infect. Dis. 20:191 (Letter.)
20. United Nations Development Program/World Bank/World Health Organization. 1995. Tropical disease research. Progress 1975-94. Highlights 1993-94, p. 137. United Nations Development Program/World Bank/World Health Organization, Geneva.